Search results

Shorebirds Competition 2021 results.

Shorebirds Competition 2022 results.

The protein mapping workhorses of the Australian Synchrotron, Macromolecular and Microfocus crystallography beamlines, MX1 and 2, continue to support important biomedical research in the development of vaccines and new therapeutics.

Researchers from the Health Research and Technology Group at ANSTO and the University of Wollongong have developed a new device that could improve the quality control of accelerator-based boron neutron capture therapy, a promising radiation therapy for treating aggressive cancers. 

With a well-established portfolio of nuclear research and the operation of Australia's only nuclear reactor OPAL, ANSTO scientists conduct both fundamental and applied research on fuel for current, advanced, and future nuclear technology systems.

The National Deuteration Facility offers access to deuterated molecules prepared by both in vivo biodeuteration and chemical deuteration techniques.

Timetable and Teams links

At ANSTO we understand that diverse teams produce better outcomes – and we value the merit that a diverse perspective can bring to the quality and outcomes of our work, and the way we get the job done.

(ANSTO) has welcomed the launch of the new National Science Statement and revitalised National Science and Research Priorities by Minister for Industry and Science, The Hon Ed Husic MP and Australia’s Chief Scientist, Dr Cathy Foley AO PSM.

By submitting a proposal for Merit Access to ANSTO’s Biosciences, Centre for Accelerator Science, Isotope Tracing, Nuclear Stewardship or the Vivarium capabilities, you are agreeing to the following Terms and Conditions. These Terms and Conditions apply to external merit researchers, scientific collaborators and partners unless there is a specific agreement in place between ANSTO and the home institution of the Principal Investigator.

ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.

ANSTO addresses key scientific questions in the nuclear fuel cycle for both the current generation of nuclear reactors and future systems.

This program uses ANSTO’s nuclear capabilities to identify, quantify, and monitor the mechanisms which cause, or influence the development and progression of chronic diseases.

Think Science! 2025 Summary and results

Timetable and Teams links

ANSTO has in-house expertise in the operation and development of accelerator systems.

Think Science! 2023 Summary and Results